Literature DB >> 8806498

Neutralization of SIVmac239/17E in lymphocyte cultures involves virus strain-specific linear and conformational epitopes encoded by different regions of the env gene including the "V3" domain.

Z Wu1, G Qian, Q L Zhen, O Narayan, E B Stephens.   

Abstract

SIVmac251 and its closely related derivatives SIVmac239 and SIVmac239/17E vary greatly in their susceptibility to neutralization with homologous and heterologous antisera. Whereas SIVmac251 induces homologous neutralizing antibodies, the antibodies induced by SIVmac239 rarely neutralize infectivity of this virus in lymphocyte cultures. In contrast, SIVmac239/17E is remarkably susceptible to neutralization with homologous and heterologous antisera induced by other strains of SIVmac. In this study, we studied the molecular basis for the neutralization of SIVmac239/17E. Using chimeric viruses in which different regions of the env gene of both SIVmac239 and SIVmac239/17E were inserted into a background of either of the parental genomes, we showed that the newly acquired neutralization properties of SIVmac239/17E were attributable to amino acid substitutions between the V2 and V4 regions of gp 120. Site-directed mutagenesis of the env gene in this region showed that the arginine substitutions at positions 334 and/or 340 within the "V3" domain were fundamental to virus neutralization but other substitutions in the V2-V4 region added to the ease of its neutralization since it became neutralizable with much higher dilutions of serum. The molecular determinants for neutralization of this virus are distinct from those reported as responsible for neutralization of SIVmac251 and both are distinct from SIVmac239.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8806498     DOI: 10.1006/viro.1996.0409

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  6 in total

1.  Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein.

Authors:  A L Edinger; M Ahuja; T Sung; K C Baxter; B Haggarty; R W Doms; J A Hoxie
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Characterization of a macaque recombinant monoclonal antibody that binds to a CD4-induced epitope and neutralizes simian immunodeficiency virus.

Authors:  J Glamann; V M Hirsch
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

3.  Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies.

Authors:  B Chackerian; L M Rudensey; J Overbaugh
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex.

Authors:  T R Fouts; J M Binley; A Trkola; J E Robinson; J P Moore
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

Review 5.  Nonhuman primate models of NeuroAIDS.

Authors:  Rachel Williams; Sirosh Bokhari; Peter Silverstein; David Pinson; Anil Kumar; Shilpa Buch
Journal:  J Neurovirol       Date:  2008-08       Impact factor: 2.643

6.  Modified Newcastle Disease virus as an improved vaccine vector against Simian Immunodeficiency virus.

Authors:  Vinoth K Manoharan; Sunil K Khattar; Celia C LaBranche; David C Montefiori; Siba K Samal
Journal:  Sci Rep       Date:  2018-06-12       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.